Results · Apr-Jun 2026
Aarti Drugs Q1 FY27 results
Sales grew 19% to ₹703 crore from ₹591 crore in Apr-Jun 2025.
Operating profit grew 33% to ₹98.2 crore, an operating margin of 14.0% (up 1.4 points from a year ago).
Net profit fell 7% to ₹50.1 crore from ₹54 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −2%, net profit −9%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 702.8 | 590.5 | +19% |
| Operating profit (EBITDA) | 98.2 | 74.1 | +33% |
| Operating margin | 14.0% | 12.5% | +1.4 pts |
| Net profit | 50.1 | 54.0 | −7% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.